New Zealand markets open in 4 hours 16 minutes
  • NZX 50

    12,728.69
    -1.21 (-0.01%)
     
  • NZD/USD

    0.7057
    -0.0013 (-0.19%)
     
  • ALL ORDS

    6,811.30
    -0.90 (-0.01%)
     
  • OIL

    45.59
    +1.04 (+2.33%)
     
  • GOLD

    1,830.10
    +11.20 (+0.62%)
     

Grass Pollen Allergy R&D Pipeline Analysis, Q4 2020 Report - ResearchAndMarkets.com

·4-min read

The "Grass Pollen Allergy R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.

This quarterly review describes the pipeline of drugs under development for Grass Pollen Allergy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Grass Pollen Allergy Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Grass Pollen Allergy disease overview, Grass Pollen Allergy types, Grass Pollen Allergy symptoms, causes, and FDA/EMA approved treatment options.

Grass Pollen Allergy Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Grass Pollen Allergy indication. The report presents near-term and long-term pipeline development trends and potential insights.

Grass Pollen Allergy Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 8 companies. Business profiles and contact details of the companies actively perusing Grass Pollen Allergy pipeline are assessed.

Grass Pollen Allergy R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Grass Pollen Allergy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Grass Pollen Allergy companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Grass Pollen Allergy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Grass Pollen Allergy Pipeline Market News and Developments during 2020

The Grass Pollen Allergy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Grass Pollen Allergy Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

  • Grass Pollen Allergy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

  • Company-company partnerships, company-institute partnerships, and investment details of companies are included

  • 8 companies are included including ALK-Abello AS, Allergy Therapeutics Plc, ASIT Biotech SA, Biomay AG, DC4U Technologies, HAL Allergy BV, Regeneron Pharmaceuticals Inc, Desentum Oy,

  • Disease overview, Pipeline trends, market analysis, and other developments

  • Potential licensing/new business opportunities in Grass Pollen Allergy pipeline market

Highlights

  • Global coverage of companies and pipeline agents

  • 2020 Trends, market analysis, and developments

  • Potential growth opportunities

  • Comprehensive details of drug candidates

Key Topics Covered:

1. Table of Contents

1.1 List of Tables

1.2 List of Figures

2. Grass Pollen Allergy Pipeline Trends and Insights

2.1 Dominant Phase type of Grass Pollen Allergy Pipeline, 2020

2.2 Most focused Mechanism of Action in Grass Pollen Allergy Pipeline

2.3 Leading type of Route of Administration during 2020

2.4 Proportion of New Molecular Entities in Grass Pollen Allergy pipeline

2.5 Active Companies Developing Grass Pollen Allergy pipeline

3. Grass Pollen Allergy Disease Types, Symptoms, Causes, and Available Treatment Options

3.1 Disease Overview

3.2 Types

3.3 Symptoms

3.4 Approved Treatment Options

4. Grass Pollen Allergy Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts

  • ALK-Abello AS

  • Allergy Therapeutics Plc

  • ASIT Biotech SA

  • Biomay AG

  • DC4U Technologies

  • HAL Allergy BV

  • Regeneron Pharmaceuticals Inc

  • Desentum Oy

5. Grass Pollen Allergy Pipeline Drug Profiles

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. Grass Pollen Allergy Pipeline Market News and Developments during 2020

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ri0htu

View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006017/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900